Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05318976
Other study ID # XPro1595-AD-02
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 28, 2022
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Inmune Bio, Inc.
Contact INmune Bio
Phone (858)964-3720
Email trials@inmunebio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.


Description:

This trial is a randomized clinical study using XPro1595 to treat patients with Early Alzheimer's Disease with biomarkers of inflammation (ADi). Early ADi patients are defined as patients with Mild Alzheimer's Disease or Mild Cognitive Impairment with a biomarker of inflammation.


Recruitment information / eligibility

Status Recruiting
Enrollment 201
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria: To be eligible for study entry, patients must satisfy all of the following criteria: - Adult patients 50 years to = 85 years of age at the time of consent; - Meets the diagnostic criteria of MCI of probable Alzheimer's disease (Jack et al. 2018; NIAAA) or mild dementia as clinically described in McKhann, (2011) and corresponding to stages 3 or 4 of the revised AD staging system (Jack, 2018); - Either currently or previously (in pre-AD condition) literate and capable of reading, writing, and communicating effectively with others; - Residence in an assisted living is allowed as is personal assistances provided in the home, however at time of enrollment participant must be able to perform most ADL with minimal assistance, and participant must be permitted sufficient independence to allow assessment of change in ADL; - Has a study partner for the duration of the trial who either lives in the same household or interacts with the patient at least 4 hours per day and on at least 4 days per week, who is knowledgeable about the patient's daytime and night-time behaviors and who can be available to attend all clinic visits in person at which caregiver assessments are performed. Exclusion Criteria: Patients will be excluded from the study if 1 or more of the following criteria are applicable: - Have any contraindications to MRI scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in-skull and cardiac devices other than those approved as safe for use in MRI scanners); - Receives considerable help to carry out basic ADL living either in the home or as a resident in a nursing home or similar facility; - Lifetime history of a major psychiatric disorder including schizophrenia and bipolar disorder. Major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime. Major depressive episode during the past 5 years that is judged by the clinical team unlikely to have been part of Alzheimer's prodrome. History of suicidality. History of substance abuse within 12 months; use of cannabis or cannabis products within 6 months of consent; - Enrolled in another clinical trial where patients receive treatment with an investigational drug or treatment device or have received treatment on another AD clinical trial within the last 60 days from Day 1; - A prior organ or stem cell transplant; - Seated blood pressure of = 165/105 mmHg at Screening.

Study Design


Intervention

Drug:
XPro1595
XPro1595 will be delivered by subcutaneous injection once a week
Placebo
Placebo will be delivered by subcutaneous injection once a week

Locations

Country Name City State
Australia INmune Bio Investigational Site Adelaide South Australia
Australia INmune Bio Investigational Site Box Hill Victoria
Australia INmune Bio Investigational Site Carlton Victoria
Australia INmune Bio Investigational Site Darlinghurst New South Wales
Australia INmune Bio Investigational Site Ivanhoe Victoria
Australia INmune Bio Investigational Site Macquarie Park New South Wales
Australia INmune Bio Investigational Site Parkville Victoria
Australia INmune Bio Investigational Site Perth Western Australia
Canada INmune Bio Investigational Site Ottawa Ontario
Canada INmune Bio Investigational Site Toronto Ontario
Germany INmune Bio Investigational Site Berlin
Poland INmune Bio Investigational Site Bialystok
United Kingdom INmune Bio Investigational Site Birmingham
United Kingdom INmune Bio Investigational Site Bristol
United Kingdom INmune Bio Investigational Site Guildford
United Kingdom INmune Bio Investigational Site London
United Kingdom INmune Bio Investigational Site Motherwell
United Kingdom INmune Bio Investigational Site Plymouth
United Kingdom INmune Bio Investigational Site Winchester

Sponsors (1)

Lead Sponsor Collaborator
Inmune Bio, Inc.

Countries where clinical trial is conducted

Australia,  Canada,  Germany,  Poland,  United Kingdom, 

References & Publications (4)

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275-85. doi: 10.1001/jama.295.19.2275. Erratum In: JAMA. 2006 Jun 7;295(21):2482. — View Citation

Chance SA, Clover L, Cousijn H, Currah L, Pettingill R, Esiri MM. Microanatomical correlates of cognitive ability and decline: normal ageing, MCI, and Alzheimer's disease. Cereb Cortex. 2011 Aug;21(8):1870-8. doi: 10.1093/cercor/bhq264. Epub 2011 Jan 14. — View Citation

Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis. CNS Drugs. 2016 Nov;30(11):1111-1120. doi: 10.1007/s40263-016-0374-z. — View Citation

Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev. 2012 Oct;64(4):1004-26. doi: 10.1124/pr.112.005850. Epub 2012 Sep 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change in Goal Attainment Scale (GAS) Change in individual goals based on the Goal Attainment Scale (GAS)
The achievement of each goal is rated on a 5-point attainment scale (-2, -1, 0, +1, +2) to allow standardized scoring of personalized outcomes. A participant's overall goal attainment is quantified using a formula that takes into account the number of goals that have been set, and the extent to which they are correlated with each other. For each identified goal area, the caregiver will be asked to give a detailed description of the patient's current (baseline) status and goal status, which will be recorded at the -1 and 0 levels on the 5-point scale, respectively. The remaining levels of the scale will then be set: somewhat better than the goal (+1), much better than the goal (+2), and much worse than the goal (-2).
To evaluate the effect of XPro1595 compared with placebo on goal attainment scores
24 Weeks
Primary Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) Change in the Early and Mild Alzheimer's cognitive composite (EMACC) from Baseline to Week 24 in the following assessments:
International Shopping List Test-Immediate recall (Word List learning Test)
Digit Span Forward and Backward
Category Fluency Test (DKEFS)
Letter Fluency Test (DKEFS)
Trail Making Test Parts A and B
Digit Symbol Coding Test
To assess the efficacy of XPro1595 compared with placebo on cognitive performance in patients with mild AD
24 Weeks
Secondary Change in Clinical Dementia Rating (CDR) Change from Baseline to Week 24 in Clinical Dementia Rating Scale (CDR)
The CDR scale is a clinician-rated dementia staging system that tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgement, and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5-point scale in which None = 0, Questionable = 0.5, Mild = 1, Moderate = 2, and Severe = 3. The global CDR score is established by clinical scoring rules and has values of 0 (no dementia), 0.5, (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.
To assess the effect of XPro1595 compared with placebo on cognition and global function in patients with mild AD
24 Weeks
Secondary Change in apparent fiber density (AFD) Change from Baseline to Week 24 in apparent fiber density (AFD)
To assess the efficacy of XPro1595 compared with placebo on axonal integrity in patients with mild AD
24 Weeks
Secondary Change in Everyday Cognition (E-Cog) Change from Baseline to Week 24 in Everyday Cognition (E-Cog)
To evaluate the effect of XPro1595 compared with placebo on E-Cog
24 Weeks
Secondary Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Change from Baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
To assess the effect of XPro1595 compared with placebo on ADL in patients with mild AD.
24 Weeks
Secondary Change in myelin content Change from Baseline to Week 24 in free-water-corrected tissue Radial diffusivity and 1 of the following i) MRI-specific myelin contrast: ii) a magnetization transfer ratio (MTR) iii) an inhomogeneous magnetization transfer (MT) or iv) an myelin water fraction (MWF) map
To assess the efficacy of XPro1595 compared with placebo on myelin in patients with mild AD.
24 Weeks
Secondary Change in non-cognitive behavioral symptoms Change from Baseline to Week 24 in (Neuropsychiatric Inventory [NPI] caregiver items)
To assess the effect of XPro1595 compared with placebo on noncognitive behavioral symptoms in patients with mild AD
24 Weeks
Secondary Change in gray matter integrity Change from Baseline to Week 24 in Cortical Disarray Measurement (CDM®)
To assess the efficacy of XPro1595 compared with placebo on gray matter integrity in patients with mild AD
24 Weeks
Secondary Change in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid) Number of participants with a reduction in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration amyloid) from Baseline to Week 24.
To assess the efficacy of XPro1595 compared with placebo on blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker amyloid).
24 Weeks
Secondary Change in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau) Change from Baseline to Week 24 in blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)
To assess the efficacy of XPro1595 compared with placebo on blood inflammatory and neurodegeneration biomarkers (on blood inflammatory and neurodegeneration biomarker pTau)
24 Weeks
Secondary Change in brain structure neurodegeneration Changes from Baseline to Week 24 in volumetric magnetic resonance imaging (MRI)
To assess the efficacy of XPro1595 compared with placebo on brain structure neurodegeneration
24 Weeks
Secondary Number of participants who experience adverse events and serious adverse events Clinically significant abnormalities of laboratory values, physical findings, electrocardiogram findings and other safety assessments will be recorded as adverse events if the findings meet the defined criteria for adverse events. Baseline up to 28 days post last dose
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A